S&P 500   3,971.25 (+0.95%)
DOW   33,842.92 (+0.73%)
QQQ   284.18 (+1.30%)
AAPL   142.86 (+1.36%)
MSFT   248.15 (+1.55%)
META   115.41 (+1.30%)
GOOGL   94.47 (-0.50%)
AMZN   90.29 (+2.07%)
TSLA   173.23 (-0.47%)
NVDA   169.02 (+4.85%)
NIO   13.42 (+6.68%)
BABA   94.07 (+6.50%)
AMD   69.99 (-0.21%)
T   19.14 (-0.83%)
MU   55.61 (+3.33%)
CGC   3.12 (-3.70%)
F   13.13 (+0.23%)
GE   83.20 (-2.12%)
DIS   92.88 (+0.79%)
AMC   6.21 (+2.64%)
PYPL   74.78 (+0.48%)
PFE   51.54 (+2.59%)
NFLX   310.22 (+0.58%)
S&P 500   3,971.25 (+0.95%)
DOW   33,842.92 (+0.73%)
QQQ   284.18 (+1.30%)
AAPL   142.86 (+1.36%)
MSFT   248.15 (+1.55%)
META   115.41 (+1.30%)
GOOGL   94.47 (-0.50%)
AMZN   90.29 (+2.07%)
TSLA   173.23 (-0.47%)
NVDA   169.02 (+4.85%)
NIO   13.42 (+6.68%)
BABA   94.07 (+6.50%)
AMD   69.99 (-0.21%)
T   19.14 (-0.83%)
MU   55.61 (+3.33%)
CGC   3.12 (-3.70%)
F   13.13 (+0.23%)
GE   83.20 (-2.12%)
DIS   92.88 (+0.79%)
AMC   6.21 (+2.64%)
PYPL   74.78 (+0.48%)
PFE   51.54 (+2.59%)
NFLX   310.22 (+0.58%)
S&P 500   3,971.25 (+0.95%)
DOW   33,842.92 (+0.73%)
QQQ   284.18 (+1.30%)
AAPL   142.86 (+1.36%)
MSFT   248.15 (+1.55%)
META   115.41 (+1.30%)
GOOGL   94.47 (-0.50%)
AMZN   90.29 (+2.07%)
TSLA   173.23 (-0.47%)
NVDA   169.02 (+4.85%)
NIO   13.42 (+6.68%)
BABA   94.07 (+6.50%)
AMD   69.99 (-0.21%)
T   19.14 (-0.83%)
MU   55.61 (+3.33%)
CGC   3.12 (-3.70%)
F   13.13 (+0.23%)
GE   83.20 (-2.12%)
DIS   92.88 (+0.79%)
AMC   6.21 (+2.64%)
PYPL   74.78 (+0.48%)
PFE   51.54 (+2.59%)
NFLX   310.22 (+0.58%)
S&P 500   3,971.25 (+0.95%)
DOW   33,842.92 (+0.73%)
QQQ   284.18 (+1.30%)
AAPL   142.86 (+1.36%)
MSFT   248.15 (+1.55%)
META   115.41 (+1.30%)
GOOGL   94.47 (-0.50%)
AMZN   90.29 (+2.07%)
TSLA   173.23 (-0.47%)
NVDA   169.02 (+4.85%)
NIO   13.42 (+6.68%)
BABA   94.07 (+6.50%)
AMD   69.99 (-0.21%)
T   19.14 (-0.83%)
MU   55.61 (+3.33%)
CGC   3.12 (-3.70%)
F   13.13 (+0.23%)
GE   83.20 (-2.12%)
DIS   92.88 (+0.79%)
AMC   6.21 (+2.64%)
PYPL   74.78 (+0.48%)
PFE   51.54 (+2.59%)
NFLX   310.22 (+0.58%)
NASDAQ:NUVL

Nuvalent - NUVL Stock Forecast, Price & News

$30.80
-0.17 (-0.55%)
(As of 12/8/2022 01:09 PM ET)
Add
Compare
Today's Range
$30.51
$31.59
50-Day Range
$18.46
$36.03
52-Week Range
$7.09
$40.43
Volume
2,152 shs
Average Volume
254,847 shs
Market Capitalization
$1.74 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.00

Nuvalent MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
62.3% Upside
$50.00 Price Target
Short Interest
Healthy
5.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.13mentions of Nuvalent in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$3.96 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.55) to ($2.00) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

415th out of 1,027 stocks

Pharmaceutical Preparations Industry

178th out of 503 stocks

NUVL stock logo

About Nuvalent (NASDAQ:NUVL) Stock

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Receive NUVL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvalent and its competitors with MarketBeat's FREE daily newsletter.

NUVL Stock News Headlines

Nuvalent Director Makes $5.00M Stock Purchase
Nuvalent Announces Public Offering of Common Stock
Why Nuvalent Shares Are Surging 45% Today?
Nuvalent Has Made a Base Pattern on the Charts
Nuvalent Has Begun the Bottoming Process
See More Headlines
Receive NUVL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvalent and its competitors with MarketBeat's FREE daily newsletter.

NUVL Company Calendar

Last Earnings
11/10/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
4/04/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NUVL
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$50.00
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+62.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-46,340,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.90 per share

Miscellaneous

Free Float
47,529,000
Market Cap
$1.74 billion
Optionable
Not Optionable
Beta
1.60

Key Executives

  • Dr. James R. Porter Ph.D. (Age 46)
    CEO, Pres & Director
    Comp: $778.59k
  • Prof. Matthew D. Shair Ph.D. (Age 53)
    Founder, Head of Scientific Advisory Board & Director
    Comp: $359.46k
  • Ms. Deborah Ann Miller J.D. (Age 46)
    Ph.D., Chief Legal Officer & Sec.
    Comp: $595.96k
  • Dr. Christopher D. Turner M.D. (Age 53)
    Chief Medical Officer
    Comp: $567.26k
  • Ms. Alex Balcom CPA (Age 37)
    M.B.A., CFO & Treasurer
  • Dr. Benjamin Lane
    Sr. VP of Technical Operations
  • Mr. Matthew Metivier
    VP of HR
  • Ms. Darlene Noci (Age 45)
    Chief Devel. Officer













NUVL Stock - Frequently Asked Questions

Should I buy or sell Nuvalent stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nuvalent in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NUVL shares.
View NUVL analyst ratings
or view top-rated stocks.

What is Nuvalent's stock price forecast for 2023?

1 equities research analysts have issued 12 month target prices for Nuvalent's stock. Their NUVL share price forecasts range from $50.00 to $50.00. On average, they predict the company's share price to reach $50.00 in the next twelve months. This suggests a possible upside of 61.4% from the stock's current price.
View analysts price targets for NUVL
or view top-rated stocks among Wall Street analysts.

How have NUVL shares performed in 2022?

Nuvalent's stock was trading at $19.04 at the beginning of the year. Since then, NUVL shares have increased by 62.7% and is now trading at $30.97.
View the best growth stocks for 2022 here
.

Are investors shorting Nuvalent?

Nuvalent saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 2,550,000 shares, a decrease of 23.2% from the October 31st total of 3,320,000 shares. Based on an average daily trading volume, of 340,400 shares, the short-interest ratio is currently 7.5 days. Approximately 6.0% of the shares of the company are sold short.
View Nuvalent's Short Interest
.

When is Nuvalent's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our NUVL earnings forecast
.

How were Nuvalent's earnings last quarter?

Nuvalent, Inc. (NASDAQ:NUVL) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.14.

When did Nuvalent IPO?

(NUVL) raised $151 million in an initial public offering on Thursday, July 29th 2021. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share.

What is Nuvalent's stock symbol?

Nuvalent trades on the NASDAQ under the ticker symbol "NUVL."

Who are Nuvalent's major shareholders?

Nuvalent's stock is owned by many different institutional and retail investors. Top institutional investors include Fairmount Funds Management LLC (4.31%), Vanguard Group Inc. (2.98%), BlackRock Inc. (2.92%), State Street Corp (0.61%), Marshall Wace LLP (0.17%) and Victory Capital Management Inc. (0.13%). Insiders that own company stock include Darlene Noci, Deborah Ann Miller and Matthew Shair.
View institutional ownership trends
.

How do I buy shares of Nuvalent?

Shares of NUVL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nuvalent's stock price today?

One share of NUVL stock can currently be purchased for approximately $30.97.

How much money does Nuvalent make?

Nuvalent (NASDAQ:NUVL) has a market capitalization of $1.75 billion. The company earns $-46,340,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis.

How can I contact Nuvalent?

The official website for the company is www.nuvalent.com. The company can be reached via phone at 857-357-7000 or via email at ir@nuvalent.com.

This page (NASDAQ:NUVL) was last updated on 12/8/2022 by MarketBeat.com Staff